Saquinavir Mesylate

For research use only. Not for therapeutic Use.

  • CAT Number: I001850
  • CAS Number: 149845-06-7
  • Molecular Formula: C38H50N6O5 • CH3SO3H
  • Molecular Weight: 767
  • Purity: ≥95%
Inquiry Now

<p style=/line-height:25px/>Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy.<br>IC50 Value:<br>Target: HIV Protease<br>Saquinavir is a protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments. HIV protease is vital for both viral replication within the cell and release of mature viral particles from an infected cell. Saquinavir binds to the active site of the viral protease and prevents cleavage of viral polyproteins, preventing maturation of the virus. Saquinavir inhibits both HIV-1 and HIV-2 proteases.Studies have also looked at Saquinavir as a possible anti-cancer agent.</p>


Catalog Number I001850
CAS Number 149845-06-7
Synonyms

(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide;methanesulfonic acid

Molecular Formula C38H50N6O5 • CH3SO3H
Purity ≥95%
Target HIV Protease
Solubility 10 mM in DMSO
Storage Store at -20°C
InChIKey IRHXGOXEBNJUSN-YOXDLBRISA-N
Reference

<p style=/line-height:25px/>
<br>[1]. Kaldor et al (1995) Isophthalic acid derivatives: amino acid surrogates for the inhibition of HIV-1 protease. Bioorg.Med.Chem.Lett. 5 721.
<br>[2]. Yerino GA, Halabe EK, Zini E, Feleder EC. Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjects. Arzneimittelforschung. 2011;61(8):481-7.
<br>[3]. Branham ML, Moyo T, Govender T. Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement. Eur J Pharm Biopharm. 2012 Jan;80(1):194-202.
<br>[4]. Brouwers J, Vermeire K, Grammen C, Schols D, Augustijns P. Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: a case study with saquinavir. Antiviral Res. 2011 Aug;91(2):217-23.
<br>[5]. Knechten H, Lutz T, Pulik P, Martin T, Tappe A, Jaeger H. Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate.
</p>

Request a Quote